- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Premier Biomedical is increasing the CBD in its CBD Hemp Oil 96-hour Skin Patch and oil-based CBD Hemp Oil Roll-on products.
Premier Biomedical (OTCQB:BIEI) is increasing the CBD in its CBD Hemp Oil 96-hour Skin Patch and oil-based CBD Hemp Oil Roll-on products.
As quoted in the press release:
The skin patch is increasing its CBD content to 50 mg, while maintaining its current selling price of $20. Roll-on applicators are currently available in two forms — 110 mg CBD oil-based with sage scent, and 120mg CBD water-based lavender scent. A new, stronger oil-based sage scented roll-on with 150mg of CBD will be available by the end of the third quarter. These higher content CBD products will be available through their website, www.painreliefmeds.com, and at select pharmacies and pain & wellness centers.
William Hartman CEO and President of Premier Biomedical stated, “We have decided to make these improvements so that we can provide the highest level of CBD for comparable products to our customers, along with increased value. Our mission is to continuously improve our products and expand our product offerings to meet the needs of our customers.”
“Based on feedback from our customers, through unsolicited reviews and testimonials on our website, we are encouraged that these products can be a possible replacement for dangerous opioid pain relief narcotics for many types of pain.”
Click here to read the full press release.
Source: www.marketwired.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.